Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes

NCT05850871 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT05850871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05850871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes
Lead sponsor
Qianfoshan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 6, 2023
Completion date
January 31, 2025
Enrollment
427 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carbapenem-resistant enterobacteriaceae infection